FindTrial
Sign In

Comparing Affected and Unaffected Skin in Psoriasis to Discover New Treatments

Exploring Biomarkers In Lesioned And Non Lesioned Skin Of Psoriasis Patients For Novel Drug Target Identification - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112194
Enrollment
41
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Sri Ramachandra Institute of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 to 65 years 2. Clinically diagnosed with chronic plaque psoriasis by a dermatologist (confirmed by PASI score or biopsy if needed) 3. Mild to moderate severity (PASI score between 3 and 12) 4. Not currently receiving systemic immunosuppressive therapy or biologics (within the past 4 weeks) 5. Willing to undergo skin biopsy and provide blood samples 6. Capable of giving informed consent

Exclusion criteria

Exclusion criteria: 1. Presence of other autoimmune or inflammatory skin diseases (eg lupus, eczema, lichen planus) 2. History of psoriatic arthritis or joint involvement 3. Use of systemic corticosteroids, immunosuppressants, or biologics within the past month 4. Pregnant or breastfeeding women 5. Presence of chronic infections (eg tuberculosis, hepatitis B and C, HIV) 6. Known malignancies or serious systemic illness (eg uncontrolled diabetes, renal failure) 7. Participation in another clinical study in the last 3 months

Design outcomes

Primary

MeasureTime frame
1. To identify molecular targets selectively expressed in inflamed tissues by comparing markers between lesional and non-lesional cells from psoriasis patients. 2. To investigate the role of the BAFF/APRIL signalling axis and metabolic changes in modulating immune cell differentiation in the pathogenesis of psoriasis and in tissue-resident memory T (Trm) cellsTimepoint: The tissue sample will be taken only once so baseline time point—

Secondary

MeasureTime frame
To investigate the prevalence of other autoimmune diseases among the family members of psoriasis patientsTimepoint: Single time only—

Countries

India

Contacts

Public ContactHemapriya Veeraraghavan

Sri Ramachandra Institute of Higher Education and Research

murugesan.a@sriramachandra.edu.in8870151588

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026